The Quantellect read.As of Nov 19, 2026, 3 active firms cover Arcosa Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $125.00 to $150.00, so the covering firms are broadly aligned. The average target of $138.33 sits 7% below the current $149.15. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -9% this year and 9% next, consensus EPS building from about $0.99 next quarter toward $4.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$138.33
-7.3% downside
Average target across 3 active firms as of Nov 19, 2026 vs $149.15 current
Highest Target$150.00
Average Target$138.33
Lowest Target$125.00
Detailed analyst forecasts for ACA
Showing 1–2 of 2 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate ACA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ACA EPS & revenue forecast
EPS · NEXT QUARTER
$0.99
Range $0.93 – $1.06 · 3 analysts · -14% YoY
Next period, 3 analysts expect Arcosa Inc to earn $0.99 a share (range $0.93 – $1.06), versus $1.15 a year earlier. Full-year consensus is $4.31, growing to $4.91 the year after.
REVENUE · NEXT QUARTER
$638.7M
Range $635.8M – $643.0M · 3 analysts · -9% YoY
Revenue is expected to reach $638.7M (range $635.8M – $643.0M), -9.0% year-over-year. Full-year consensus is $2.6B, rising to $2.8B next year.
Top analysts covering Arcosa Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACA.
#1
Brent Thielman
DA Davidson · Rank #19
Buy
$125.00-16.2% to target
Overall win rate
52%
+ Follow
#2
Adam Seiden
Barclays · Rank #374
Buy
$140.00-6.1% to target
Overall win rate
38%
+ Follow
#3
Ian Zaffino
Oppenheimer · Rank #390
Buy
$110.00-26.2% to target
Overall win rate
38%
+ Follow
#4
Brent Thielman
Oppenheimer
Neutral
$150.00+0.6% to target
Coverage
—
+ Follow
#5
TG
Trey Grooms
Stephens & Co.
Neutral
$150.00+0.6% to target
Coverage
—
+ Follow
ACA stock forecast FAQ
What is ACA's average 12-month price target?+
The 3 active firms with a live target average $138.33 for Arcosa Inc over the next 12 months, ranging from a $150.00 high to a $125.00 low, as of Nov 19, 2026.
Is ACA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ACA?+
The Street-high target is $150.00 (Oppenheimer), and the Street-low is $125.00 (DA Davidson). The average of all 3 active-firm targets is $138.33.
How many active Wall Street firms cover ACA?+
3 active firms have a recognized rating on Arcosa Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ACA?+
Among analysts who currently cover ACA, Brent Thielman of DA Davidson has the strongest overall Quantellect track record (Rank #19). Their current call is Buy with a $125.00 target.
What is Arcosa Inc's projected EPS for next quarter?+
The consensus estimate is $0.99 per share (range $0.93 – $1.06) across 3 analysts. Full-year EPS is projected at $4.31, rising to $4.91 the following year.
How much revenue is Arcosa Inc expected to report next quarter?+
Consensus revenue is $638.7M (range $635.8M – $643.0M). Full-year revenue is projected at $2.6B, growing to $2.8B next year.
Have analysts been upgrading or downgrading ACA lately?+
As of Nov 19, 2026, 3 of 3 active firms rate ACA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.